Authors
Latest:
Apalutamide Produces Deep PSA Response vs Enzalutamide in mCSPCBenjamin H. Lowentritt, MD, FACS, discusses findings from a United States real-world study of patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide.
Latest:
Overcoming Atypical EGFR Challenges With a Novel ApproachByoung Chul Cho, MD, PhD, discusses the implications of the CHRYSALIS-2 study of amivantamab and lazertinib.
Latest:
CAR T Cells Engineered to Target Solid TumorsSamer A. Srour, MB, ChB, MS, discusses the design of ALLO-316, an agent investigated in the phase 2 TRAVERSE trial for patients with renal cell carcinoma.
Latest:
Evaluating Treatment in High-Risk Lung Cancer Mutations and ctDNAAlexander Spira, MD, PhD, FACP, discusses the PAPILLON trial, including its methods, design, and rationale as well as new data from the study.
Latest:
Breast Cancer Awareness Month: What to Know for Different Types of Breast CancerFor Breast Cancer Awareness Month Kristina Mirabeau-Beale, mD, MPH, and Bridget Koontz, MD, discuss the different types of breast cancer that clinicians need to be aware of.
Latest:
JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCCThe potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.
Latest:
Precision Medicine Will Drive New Standards of Care in the Post–COVID-19 WorldOnce the impact of COVID-19 begins to minimize and activities settle into a “new normal,” efforts to expand precision medicine across many diseases will resume.
Latest:
Adjuvant Nivolumab Falls Short of Disease-Free Survival End Point in Locally Advanced High-Risk RCCIn the phase 3 CheckMate 914 trial, the use of nivolumab did not meet the primary endpoint of disease-free survival when compared to a placebo in patients with localized renal cell carcinoma at a heightened risk of relapse following nephrectomy.
Latest:
The Role of Age in Bone Marrow and Stem Cell Transplants for MDSRonald L. Paquette, MD, discusses how age impacts the use of bone marrow and stem cell transplants in patients with myelodysplastic syndrome.
Latest:
Five-Year Data Confirm Benefit of Nivolumab in Upper GI CancerDavid B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
Latest:
DLBCL Subtype Response Patterns: Optimizing Treatment SelectionExperts discuss polatuzumab’s effectiveness across germinal center B-cell (GCB) and activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL) subgroups, including updates to published data. They also explore how different molecular classification methods compare in clinical practice to guide treatment selection, with insights on differential responses across specific molecular or clinical subgroups.
Latest:
Recent Advances in mCSPC and Advice for Community OncologistsSheela Tejwani, MD, highlights some exciting recent trial data and shares clinical pearls for community oncologists treating mCSPC.
Latest:
Addressing MDS Treatment Gap Post Hypomethylating FailureThe frontline standard-of-care regimen for patients with higher-risk MDS and some with lower-risk MDS remain hypomethylating agents, such as azacitidine, decitabine, and decitabine/cedazuridine.
Latest:
Real-World Outcomes of Oral Azacitidine Maintenance in AML Presented at ASH 2024Fatima Tuz Zahra, MD, discusses the methods and design of a retrospective analysis of 65 patients with acute myeloid leukemia treated with oral azacitidine maintenance after achieving complete remission.
Latest:
CAR T-Cell Therapy Access Remains Elusive, But Solutions May Be Closer Than ExpectedWidespread access to CAR T-cell therapy remains a problem, and quite a few challenges have arisen in regards to optimizing outcomes for CAR T-cell therapy in patients with hematologic malignancies and solid tumors.
Latest:
Tolerability of Teclistamab Improved with Step-Up DosingIn a discussion with Targeted Oncology, David Dingli, MD, PhD, looks at how the use of step-up dosing with tecalistimab helped avoid many serious adverse events.
Latest:
Defining the Role of Stem Cell Transplant in T-Cell LymphomaJohn Lister, MD, discusses the current role of stem cell transplant in the treatment of T-cell lymphoma, and some of the latest advances in the space.
Latest:
Future Outlooks for CAR T in Early R/R Multiple MyelomaPanelists discuss how chimeric antigen receptor (CAR) T-cell therapy could potentially be moved to earlier lines of treatment in relapsed/refractory multiple myeloma based on emerging trial data, improving outcomes through earlier intervention before patients develop treatment resistance.
Latest:
Novel Anti-CD19 CAR T-Cell Therapy Shows Efficacy in Multiple BCL SubtypesManali Kamdar, MD, MBBS, discusses the efficacy and tolerability of a phase 1 clinical trial testing a novel anti-CD19 chimeric antigen receptor T-cell product in adults with relapsed/refractory B-cell lymphoma.
Latest:
Redefining Mesothelioma and Addressing Persistent ChallengesHedy Lee Kindler, MD, shares new mesothelioma guidelines that have been released by the American Society of Clinical Oncology.
Latest:
Recent Advancements in Stem Cell TransplantsAmer Assal, MD, discusses recent advancements in the field of bone marrow and stem cell transplants at the American Society of Hematology 2023 Annual Meeting.
Latest:
Considering Mutations and Resistance in Lung Cancer to Improve Precision MedicineAnne Chiang, MD, associate professor, Medical Oncology, Yale School of Medicine, discusses hard-to-treat lung cancer and how due to recent lung cancer innovations and treatment options, the tumor is becoming increasingly heterogeneous.
Latest:
Real-World Implications of the IMpower133 Trial in ES-SCLCEric S. Nadler, MD of Texas Oncology, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment of the IMpower133 trial in patients with extensive-stage small cell lung cancer.
Latest:
Revumenib Shows Potential in Phase 2 Trial of Children and Adults With R/R KMT2Ar Acute LeukemiaA new targeted therapy showed promising response rates in pediatric and adult patients with relapsed/refractory KMT2A rearranged acute leukemia.
Latest:
Exploring Current and Future Treatment in Patients With DLBCLMitul Gandhi, MD, discusses the current landscape for patients with diffuse large B-cell lymphoma and what may be coming in the future.
Latest:
Unmet Needs in the Treatment of Patients With MDSAmy Dezern, MD, MHS, closes her discussion by emphasizing the need for more treatments in MDS.
Latest:
Managing Symptoms of Diarrhea Improves Medication Adherence in Patients Treated With AbemaciclibDose escalation may be beneficial for patients starting treatment regimens with a high incidence of toxicities that may lead to abrupt patient self-discontinuation.
Latest:
The Promise of OBX-115, a Novel TIL Therapy, in MelanomaRodabe Amaria, MD, discusses the current role of OBX-115 for the treatment of patients with checkpoint inhibitor-resistant metastatic melanoma.
Latest:
Risk Information Can Influence Clinical Decision-Making in MelanomaCutaneous melanoma is disproportionately lethal among skin cancers, and as incidence rates of cutaneous melanoma continue to rise in the United States, so does the importance of managing melanoma cases in alignment with personalized prognoses.
